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H epatocellular carcinoma (HCC) metastasizes mainly within the confines of the liver.  Metastasis to the 
heart from other carcinoma sources is not infrequent,  
but a solitary cardiac metastasis originating from HCC 
is rare and has a poor prognosis,  in part because of the 
lack of standardized therapies.  At our hospital,  one 
patient lived > 3 years after his initial diagnosis of a sol-
itary cardiac metastasis originating from HCC following 
the curative resection of the cancerous area of his liver.  
The patient received therapy comprised of three courses 
of combined radiotherapy and chemotherapy.  He was 
able to live a nearly normal daily life until multiple lung 
metastases were discovered.  We report the case in 
detail.
Case Report
A 64-year-old Japanese hepatitis B virus-positive 
male was admitted to our hospital for a S7 liver tumor 
discovered by abdominal ultrasonography.  The patient 
underwent an S7 segmentectomy in September 2013.  
The preoperative ECG was normal.  Microscopically,  
the tumor was moderately differentiated hepatocellular 
carcinoma,  measuring 6.5 cm;  s0,  vp1,  vv0,  va0,  b0,  
with a pathological stage of III,  based on the general 
rules for clinical and pathological studies of primary 
liver cancer in Japan (Fig. 1).  In June 2015,  19 months 
after the segmentectomy,  a CT/PET-CT scan result 
revealed a 28 × 43-mm tumor in the right ventricle that 
was not recognized in testing prior to the hepatectomy.  
The tumor was clinically diagnosed as solitary recurrent 
HCC (Figs. 2 , 3).  An MRI exam was not performed due 
to the patient’s extensive body tattoos.  Echocardiography 
demonstrated a slightly protruding right ventricle 
tumor suggestive of endomyocardial metastasis (Fig. 4).
The patient’s serum PIVKA-II was elevated at 
16,500 mAU/ml,  a figure that had normalized after the 
hepatectomy.  The laboratory data at recurrence are 
shown in Table 1.  Although no other metastases were 
found,  resection of the cardiac tumor was not indi-
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Cardiac metastasis originating from hepatocellular carcinoma (HCC) is a rare condition with a poor prognosis.  
No therapeutic standards for cardiac metastasis originating from HCC have been established.  At 19 months 
after a curative hepatectomy,  a 64-year-old Japanese hepatitis B virus-positive male patient experienced solitary 
cardiac metastasis originating from HCC.  The cardiac tumor was discovered in the right ventricle.  The patient 
received three courses of radiotherapy and chemotherapy and survived > 3 years after the initial diagnosis of 
cardiac metastasis.  His case demonstrates that radiotherapy combined with chemotherapy can be an effective 
treatment for cardiac metastasis.
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Fig. 1　 Resected specimen.  A,  S7 liver 282 g; B,  cross-sectional slices of the liver tumor; C and D,  microscopic images of the tumor 
by HE stain.
cated,  because (1) a complete resection was projected to 
be exceedingly difficult,  and (2) resection could have 
led to systemic spread of the tumor.  Thereafter,  because 
the patient had untreated hypertension,  tegafur-uracil 
therapy was initiated at a daily dose of 600 mg.  This 
therapy was halted after 4 months of use because the 
patient experienced nausea.
In November 2015,  the patient was taken to the hos-
pital with sudden palpitations and dyspnea.  No mur-
murs or rales were audible.  An ECG test in the emer-
gency room showed inverted T waves and bi-phased P 
waves.  The tumor was found to have enlarged to 
41 × 59 mm,  and it induced right ventricular outflow 
tract stenosis (which was thought to be the cause of the 
dyspnea).  The right ventricular outflow tract flow was 
3.8 m/sec,  which was faster than before (1.7 m/sec 
when the cardiac metastasis was initially detected).  The 
patient underwent 50 Gy of palliative radiotherapy.  Ten 
MV X-ray wedge pair fields were given as the course of 
radiotherapy.
Within 1 month after the radiotherapy,  the patient’s 
dyspnea and appetite improved and in another 
2 months,  the tumor was slightly reduced in size 
(34 × 48 mm).  Chemotherapy was reinitiated,  but the 
tumor continued to increase in size and the patient’s 
symptoms gradually grew more severe.  Palliative radio-
therapy was carried out in June 2016 (30 Gy) and 
August 2017 (20 Gy).  After each radiotherapy session,  
the serum PIVKA-II level was decreased.  Although 
pericardial effusion was detected afterward,  pericar-
diocentesis was deemed too difficult to conduct from a 
technical perspective.  Echocardiography did not indi-
cate endocarditis or myocarditis as signs of adverse 
effects of radiotherapy.  No other severe complications 
occurred.
A CT scan in August 2018 revealed multiple lung 
metastases (Fig. 5),  although no abnormal lesions had 
been revealed by a chest X-ray exam earlier in June.  
After the lung metastases were discovered,  oral 
sorafenib therapy was initiated.  The patient was later 
taken to our hospital in cardiopulmonary arrest and 
died in October 2018,  61 months after the initial hepa-
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Table 1　 Laboratory data at recurrence
WBC 7,300 /mm3 PT-% 46.4 % γ-GTP 31 IU/l
RBC 459×104 /mm3 PT-INR 1.57 LDH 346 IU/l
Hb 17.1 g/dl Alb 3.7 g/dl BUN 26.6 mg/dl
Ht 52.2 % CRP 0.09 mg/dl Cr 1.16 mg/dl
Plt 12.3×103 /mm3 T-Bil 3.40 mg/dl AMY 96 IU/l
Neutrphil 41.9 % D-Bil 1.20 mg/dl HbA1c 5.4 %
Lymphocyte 49.7 % AST 55 IU/l AFP 2.5 ng/ml
Monocyte 6.3 % ALT 74 IU/l PIVKAⅡ 16,500 mAU/ml
Eosinophil 1.2 % ALP 248 IU/l
Basophil 0.9 %
Fig. 4　 Echocardiography
Fig. 5　 Multiple lung metastases.
tectomy and 42 months after the diagnosis of cardiac 
metastasis.  A decision was made to not perform an 
autopsy.  The relationship between the patient’s treat-
ment and his serum PIVKA-II levels is indicated in 
Fig. 6 as a summary of the clinical course.
Discussion
Abdominal surgeons seldom encounter metastatic 
tumors in the heart.  Hepatocellular carcinoma in the 
liver can metastasize into the right atrium through the 
inferior vena cava.  Usually,  however,  such a situation is 
not considered to be distant or hematogenous cardiac 
metastasis.
The incidence of secondary metastatic tumors to the 
pericardium,  myocardium,  great vessels,  or coronary 
arteries in the general population at autopsy is between 
0.7% and 3.5% [1].  Among post-mortem patients who 
had died of the malignancy,  however,  that figure rises 
to 25% [2].  The most common site of cardiac metasta-
sis is the pericardium (64-69%),  followed by the epicar-
dium (25-34%) and the myocardium (29-32%).  
Metastasis to the endocardium is rare (3-5%) [3].  The 
most common tumors with cardiac metastatic potential 
are carcinoma of the lung (36-39%) and breast (10-12%) 
and hematologic malignancies (10-21%) [1 , 2].
Regarding the routes of metastatic spread to the 
heart,  lymphatic spread tends to give rise to pericardial 
metastasis,  and a hematogeneous spread preferentially 
gives rise to myocardial metastasis [2].  Cardiac metas-
tases are ordinarily small and multiple.  They usually 
therefore remain clinically silent [2].  Sometimes,  how-
ever,  cardiac metastasis cases are an oncological emer-
gency,  because some patients have an outflow tract 
obstruction due to lesions that occupy space in the 
heart,  especially on the endocardium,  as was seen in 
our patient’s case.  Pericardial involvement has the 
potential to cause pericardial effusion or pericarditis.  
Epicardial and myocardial involvement could cause 
dysrhythmias or decreased cardiac output.
MRI screening is generally thought to be the best 
diagnostic option,  although this technology could not 
be used for our patient due to his extensive tattoos.  
Other assessment options include the use of multiple 
cardiac imaging planes,  which allows a more complete 
description of the anatomic relationships involved [3].  
Sato reported that careful attention to the heart using 
imaging evaluations including FDG-PET is valuable for 
the detection of the early stages of cardiac metastasis 
[4].  Echocardiography has been described as a nonin-
vasive and informative tool.  Transcatheter aspiration 
cytology could serve as a definitive diagnostic option 
[5],  although the procedure is invasive.  The scientific 
consensus [6] seems to be that an endomyocardial 
biopsy for a cardiac tumor is a reasonable procedure if a 
diagnosis cannot be established by noninvasive modali-
ties.  The main point of concern should be that any new 
cardiac symptom in a patient with a known malignancy 



















































































Fig. 6　 Treatments,  serum PIVKA-II.
might indicate the possibility of cardiac metastasis [3],  
such as that seen in the present case.
Cardiac metastatic tumor locations are right-side 
dominant.  Kawakami collected and analyzed 17 cases 
of isolated HCC metastasis to the heart [7]; 13 of the 
17 cases were right-side only,  but 2 cases were left-side 
only,  and 2 cases were of a bilateral nature.  Tastekin et 
al.  reported a rare case of left cardiac ventricular 
metastasis [8],  and they speculated that the tumor cells 
had spread via a pulmonary vein from a tumor origi-
nating in the lung.  Fukuoka also reported isolated HCC 
metastasis in the left atrium extending from lung 
metastasis through the left pulmonary vein [9].  From 
these reports,  it would seem that left-sided cardiac 
metastasis usually occurs with lung metastasis.
With regard to chemotherapy,  tegafur-uracil was the 
initial treatment of choice for our patient.  One reason 
for this selection was the patient’s untreated hyperten-
sion.  Although he had been diagnosed with hyperten-
sion,  he had never taken medication to treat the disor-
der.  Sorafenib was found to be significantly effective for 
advanced HCC by SHARP test [10],  but the effective-
ness was modest,  with the overall response rate only 2% 
and all of the responses partial.  At the time of our 
patient’s diagnosis,  some reports of Japanese patients 
indicated the effectiveness of tegafur-uracil for inoperable 
HCC [11] or HCC with distant metastasis [12].  Tanabe 
collected 16 complete remission cases and 19 partial 
response cases treated by tegafur-uracil for locally 
advanced or distant metastatic HCC [12],  and some 
reports indicate that sorafenib might cause severe cardiac 
events [13 , 14].  For the treatment of cardiac metastasis 
therefore,  close attention is warranted regarding the use 
of tyrosine kinase inhibitors.
Concerning the prognosis of patients with HCC and 
a solitary cardiac metastasis,  Kawakami reported that 
excluding three patients without a detailed prognosis,  
11 of 14 patients had died within 6 months of their 
diagnoses [6].  None of the patients in the Kawakami 
series had undergone radiotherapy.  Only one patient 
alive at 21 months after treatment had undergone sur-
gery,  and the seven other patients who had undergone 
surgery succumbed within 6 months.
 Lui analyzed 48 HCC patients with metastasis in the 
cardiac cavity [15]; only one of the patients was iso-
lated and categorized as having discontinuous cardiac 
metastasis.  The median and mean survival times from 
the time of diagnosis of cardiac metastasis were 102 days 
and 161 days,  respectively.  Takaya reported the case of 
a patient who had undergone the resection of a pedun-
culated right atrial metastasis [5].  The patient’s primary 
lesions were treated by transcatheter arterial chemoem-
bolization and radiofrequency ablation.  Six months 
later,  the patient developed lung metastasis.  The patient 
underwent chemotherapy with sorafenib but suc-
cumbed 36 months after the diagnosis.  If resection is 
being considered a treatment option for cardiac metas-
tasis,  its effectiveness should first be analyzed carefully.
There are several case reports demonstrating the 
effectiveness of external beam radiation for cardiac 
tumors.  Dasgupta describes how radiotherapy can suc-
cessfully palliate cardiac metastasis while preserving the 
patient’s quality of life [16].  In the largest report of its 
kind published thus far,  Ghiam et al.  analyzed 10 cases 
including that of an HCC patient who was treated with 
palliative radiotherapy for cardiac metastasis from dif-
ferent origins [17].  They recommended that palliative 
RT should be considered early in the management of 
patients with cardiac metastasis.  They also emphasized 
that a delay in palliative radiotherapy could potentially 
deprive such patients of an effective treatment that could 
potentially help manage symptoms.
In conclusion,  a patient treated at our hospital 
developed a solitary cardiac metastasis of HCC after 
curative hepatectomy.  He underwent 3 courses of com-
bined radiotherapy and chemotherapy and survived 
> 3 years after the initial diagnosis of cardiac metastasis.  
His case demonstrates that radiotherapy in combina-
tion with chemotherapy can be an effective treatment,  
and a palliative option,  for cardiac metastasis.
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